PITTSBURGH, Nov. 2 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Loxapine Capsules, 5 mg, 10 mg, 25 mg, and 50 mg strengths. Loxapine Capsules are the generic version of Watson Laboratories, Inc.'s Loxitane^® Capsules.

The product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements," including with regard to the immediate shipment of Loxapine Capsules. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product at the Company's facility; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.
11/02/2004
CONTACT: Media, Heather Bresch, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com/